WEBSITE BSE:532321 NSE: ZYDUSLIFE Inc. Year: 1995 Industry: Pharmaceuticals & Drugs
Last updated: 15:58
Zydus Lifesciences Limited engages within the research, development, production, advertising, distribution, and sale of pharmaceutical products in India, America, and across the world. It offers finished dosage human formulations comprising generics, branded generics, and strong point formulations, including biosimilars and vaccines; active pharmaceutical elements; animal healthcare products; and consumer well being products. The enterprise presents products within the therapeutic regions of ache control, neurology, liver disease, and different...Read More
Zydus Lifesciences Limited engages within the research, development, production, advertising, distribution, and sale of pharmaceutical products in India, America, and across the world. It offers finished dosage human formulations comprising generics, branded generics, and strong point formulations, including biosimilars and vaccines; active pharmaceutical elements; animal healthcare products; and consumer well being products. The enterprise presents products within the therapeutic regions of ache control, neurology, liver disease, and different areas. It additionally gives consumer health merchandise, which includes SugarFree and Sugarlite; Complan; EverYuth, a range of skin care merchandise; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and diverse different products. In addition, the company is developing tablets inside the regions of oncology, autoimmune disorder, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, and so forth. Further, it gives animal healthcare merchandise for diverse therapeutic areas, including anti-bacterial, NSAIDs, anti-mastitis, tonics, and hen vaccines. The corporation also engages within the retail pharmacy, and manpower supply and administration activities. The company was previously called Cadila Healthcare Limited and modified its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was incorporated in 1952 and is primarily based in Ahmedabad, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹89283 Cr.
Stock P/E 19.3
P/B 3.4
Current Price ₹887.3
Book Value ₹ 261
Face Value 1
52W High ₹1059
Dividend Yield 1.24%
52W Low ₹ 797.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 4369 | 4505 | 5534 | 6208 | 5237 | 5269 | 6528 | 6574 | 6123 | 6865 |
| Other Income | 136 | 38 | 162 | 63 | 114 | 58 | 81 | 212 | 523 | 111 |
| Total Income | 4505 | 4543 | 5696 | 6271 | 5351 | 5327 | 6609 | 6786 | 6646 | 6976 |
| Total Expenditure | 3305 | 3403 | 3909 | 4124 | 3821 | 3882 | 4402 | 4542 | 4522 | 5048 |
| Operating Profit | 1200 | 1140 | 1787 | 2147 | 1530 | 1445 | 2206 | 2243 | 2125 | 1928 |
| Interest | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 |
| Depreciation | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -220 | 0 | -34 | -85 |
| Profit Before Tax | 1007 | 926 | 1547 | 1900 | 1271 | 1184 | 1672 | 1921 | 1687 | 1353 |
| Provision for Tax | 226 | 214 | 321 | 436 | 373 | 180 | 423 | 434 | 454 | 388 |
| Profit After Tax | 781 | 712 | 1226 | 1464 | 898 | 1005 | 1249 | 1487 | 1233 | 965 |
| Adjustments | 20 | 78 | -44 | -44 | 13 | 19 | -78 | -20 | 25 | 77 |
| Profit After Adjustments | 801 | 790 | 1182 | 1420 | 911 | 1024 | 1171 | 1467 | 1259 | 1042 |
| Adjusted Earnings Per Share | 7.9 | 7.8 | 11.8 | 14.1 | 9.1 | 10.2 | 11.6 | 14.6 | 12.5 | 10.4 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 8651 | 9427 | 9377 | 11905 | 13166 | 14253 | 14404 | 15110 | 17237 | 19547 | 23242 | 26090 |
| Other Income | 57 | 117 | 147 | 133 | 209 | 117 | 75 | 391 | 475 | 369 | 460 | 927 |
| Total Income | 8709 | 9543 | 9524 | 12038 | 13374 | 14370 | 14479 | 15501 | 17712 | 19917 | 23701 | 27017 |
| Total Expenditure | 6897 | 7097 | 7472 | 9058 | 10187 | 11473 | 11018 | 11935 | 13666 | 14248 | 16348 | 18514 |
| Operating Profit | 1811 | 2446 | 2051 | 2980 | 3187 | 2897 | 3460 | 3565 | 4047 | 5668 | 7353 | 8502 |
| Interest | 68 | 53 | 63 | 111 | 196 | 342 | 186 | 127 | 130 | 81 | 191 | 393 |
| Depreciation | 287 | 292 | 373 | 539 | 599 | 697 | 670 | 713 | 723 | 764 | 916 | 1138 |
| Exceptional Income / Expenses | -10 | -3 | -0 | 0 | -10 | -364 | -205 | 113 | -604 | -14 | -220 | -339 |
| Profit Before Tax | 1446 | 2099 | 1615 | 2331 | 2382 | 1495 | 2399 | 2838 | 2590 | 4809 | 6027 | 6633 |
| Provision for Tax | 259 | 177 | 129 | 564 | 530 | 320 | 194 | 512 | 588 | 978 | 1412 | 1699 |
| Profit After Tax | 1186 | 1921 | 1486 | 1766 | 1852 | 1176 | 2206 | 2326 | 2002 | 3831 | 4615 | 4934 |
| Adjustments | -36 | 13 | 2 | 9 | -3 | 1 | -72 | 2161 | -42 | 28 | -89 | 4 |
| Profit After Adjustments | 1151 | 1934 | 1488 | 1776 | 1849 | 1177 | 2134 | 4487 | 1960 | 3860 | 4526 | 4939 |
| Adjusted Earnings Per Share | 11.2 | 18.9 | 14.5 | 17.3 | 18.1 | 11.5 | 20.8 | 43.8 | 19.4 | 38.4 | 45 | 49.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 19% | 15% | 10% | 10% |
| Operating Profit CAGR | 30% | 27% | 20% | 15% |
| PAT CAGR | 20% | 26% | 31% | 15% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -8% | 23% | 14% | 11% |
| ROE Average | 21% | 18% | 18% | 21% |
| ROCE Average | 26% | 22% | 19% | 19% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4252 | 5699 | 6960 | 8745 | 10386 | 10376 | 12992 | 17000 | 17516 | 19830 | 23953 |
| Minority's Interest | 169 | 136 | 156 | 191 | 1293 | 1335 | 1937 | 2054 | 2173 | 2272 | 2405 |
| Borrowings | 1150 | 896 | 2468 | 2555 | 3950 | 3215 | 610 | 362 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 191 | -160 | -565 | -433 | -459 | -361 | -590 | -556 | -725 | 193 | -542 |
| Total Current Liabilities | 3285 | 3461 | 5306 | 6072 | 7343 | 8269 | 7861 | 7827 | 5527 | 5340 | 9042 |
| Total Liabilities | 9047 | 10032 | 14325 | 17141 | 22513 | 22834 | 22810 | 26700 | 24494 | 27637 | 34858 |
| Fixed Assets | 3352 | 3748 | 5755 | 6483 | 12164 | 12231 | 12133 | 12189 | 11521 | 12369 | 13134 |
| Other Non-Current Assets | 1468 | 2004 | 2548 | 2428 | 1851 | 1888 | 1962 | 2250 | 2957 | 3767 | 4678 |
| Total Current Assets | 4227 | 4280 | 6022 | 8201 | 8498 | 8715 | 8716 | 12095 | 10008 | 11420 | 17046 |
| Total Assets | 9047 | 10032 | 14325 | 17141 | 22513 | 22834 | 22810 | 26700 | 24494 | 27637 | 34858 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 613 | 738 | 837 | 1593 | 1590 | 779 | 1178 | 888 | 658 | 488 | 413 |
| Cash Flow from Operating Activities | 994 | 1894 | 1312 | 919 | 1282 | 2932 | 3294 | 2105 | 2689 | 3196 | 6777 |
| Cash Flow from Investing Activities | -465 | -864 | -2872 | -974 | -4239 | -1012 | -725 | -1000 | 1535 | -1475 | -8372 |
| Cash Flow from Financing Activities | -351 | -935 | 2316 | 52 | 1885 | -1528 | -2548 | -868 | -4400 | -1779 | 2014 |
| Net Cash Inflow / Outflow | 178 | 95 | 756 | -3 | -1072 | 391 | 22 | 236 | -177 | -58 | 419 |
| Closing Cash & Cash Equivalent | 790 | 837 | 1593 | 1590 | 779 | 1178 | 1087 | 1107 | 488 | 413 | 827 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 11.24 | 18.89 | 14.53 | 17.34 | 18.05 | 11.49 | 20.84 | 43.82 | 19.37 | 38.36 | 44.99 |
| CEPS(Rs) | 14.39 | 21.62 | 18.15 | 22.51 | 23.93 | 18.28 | 28.08 | 29.68 | 26.92 | 45.68 | 54.98 |
| DPS(Rs) | 2.4 | 3.2 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 |
| Book NAV/Share(Rs) | 41.52 | 55.66 | 67.97 | 85.4 | 101.43 | 101.33 | 126.88 | 166.01 | 173.08 | 197.11 | 238.1 |
| Core EBITDA Margin(%) | 19.9 | 24.22 | 19.89 | 23.82 | 22.62 | 19.51 | 11.72 | 10.74 | 10.53 | 13.97 | 15.09 |
| EBIT Margin(%) | 17.17 | 22.37 | 17.53 | 20.42 | 19.58 | 12.89 | 8.96 | 10.03 | 8.02 | 12.89 | 13.61 |
| Pre Tax Margin(%) | 16.4 | 21.82 | 16.87 | 19.5 | 18.09 | 10.49 | 8.31 | 9.6 | 7.64 | 12.68 | 13.19 |
| PAT Margin (%) | 13.46 | 19.98 | 15.52 | 14.78 | 14.07 | 8.25 | 7.64 | 7.87 | 5.9 | 10.1 | 10.1 |
| Cash Profit Margin (%) | 16.72 | 23.02 | 19.42 | 19.28 | 18.61 | 13.13 | 9.96 | 10.28 | 8.03 | 12.12 | 12.11 |
| ROA(%) | 13.93 | 20.14 | 12.2 | 11.23 | 9.34 | 5.18 | 9.66 | 9.4 | 7.82 | 14.7 | 14.77 |
| ROE(%) | 30.85 | 38.62 | 23.47 | 22.5 | 19.36 | 11.32 | 18.88 | 15.51 | 11.6 | 20.52 | 21.08 |
| ROCE(%) | 23.21 | 28.6 | 16.52 | 18.55 | 15.89 | 10.02 | 14.38 | 15.3 | 13.64 | 24.9 | 26.06 |
| Receivable days | 56.38 | 63.29 | 76.72 | 83.72 | 99.21 | 97.49 | 42.92 | 39.94 | 41.75 | 46.37 | 36.93 |
| Inventory Days | 60.13 | 54.52 | 59.88 | 63.95 | 70.33 | 70.13 | 38.08 | 42.95 | 38.39 | 32.98 | 29.51 |
| Payable days | 129.81 | 163.78 | 170.06 | 171.49 | 167.94 | 170.61 | 189.45 | 166.64 | 145.8 | 147.51 | 151.33 |
| PER(x) | 30.96 | 16.78 | 30.51 | 21.83 | 19.2 | 23.25 | 21.16 | 7.96 | 25.37 | 26.2 | 19.69 |
| Price/Book(x) | 8.38 | 5.69 | 6.52 | 4.43 | 3.42 | 2.64 | 3.47 | 2.1 | 2.84 | 5.1 | 3.72 |
| Dividend Yield(%) | 0.69 | 1.01 | 0.72 | 0.92 | 1.01 | 1.31 | 0.79 | 0.72 | 1.22 | 0.3 | 1.24 |
| EV/Net Sales(x) | 4.35 | 3.63 | 5.23 | 3.6 | 3.25 | 2.41 | 3.39 | 2.57 | 2.92 | 5.16 | 3.84 |
| EV/Core EBITDA(x) | 20.76 | 14.01 | 23.91 | 14.38 | 13.44 | 11.87 | 14.11 | 10.88 | 12.44 | 17.78 | 12.15 |
| Net Sales Growth(%) | 19.76 | 8.96 | -0.53 | 26.97 | 10.59 | 8.26 | 1.06 | 4.9 | 14.08 | 13.4 | 18.9 |
| EBIT Growth(%) | 42.73 | 42.16 | -22.02 | 45.53 | 5.58 | -28.73 | 40.74 | 14.68 | -8.28 | 79.81 | 27.15 |
| PAT Growth(%) | 41.84 | 61.98 | -22.67 | 18.89 | 4.83 | -36.52 | 87.61 | 5.48 | -13.95 | 91.39 | 20.45 |
| EPS Growth(%) | 43.18 | 68.08 | -23.07 | 19.37 | 4.11 | -36.36 | 81.34 | 110.32 | -55.8 | 98.06 | 17.26 |
| Debt/Equity(x) | 0.62 | 0.43 | 0.75 | 0.62 | 0.76 | 0.77 | 0.35 | 0.25 | 0.07 | 0.04 | 0.13 |
| Current Ratio(x) | 1.29 | 1.24 | 1.14 | 1.35 | 1.16 | 1.05 | 1.11 | 1.55 | 1.81 | 2.14 | 1.89 |
| Quick Ratio(x) | 0.82 | 0.86 | 0.8 | 0.96 | 0.79 | 0.72 | 0.7 | 1.07 | 1.19 | 1.5 | 1.45 |
| Interest Cover(x) | 22.29 | 40.75 | 26.59 | 22.04 | 13.17 | 5.38 | 13.87 | 23.35 | 20.94 | 60.22 | 32.55 |
| Total Debt/Mcap(x) | 0.07 | 0.08 | 0.11 | 0.14 | 0.22 | 0.29 | 0.1 | 0.12 | 0.02 | 0.01 | 0.04 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.98 | 74.99 | 74.99 | 74.99 | 75 |
| FII | 4.86 | 5 | 5.72 | 5.59 | 7.52 | 7.53 | 7.32 | 7.13 | 7.34 | 7.06 |
| DII | 13.09 | 13.03 | 12.63 | 12.64 | 10.65 | 10.65 | 11.01 | 11.13 | 10.86 | 11.09 |
| Public | 7.07 | 6.99 | 6.66 | 6.8 | 6.85 | 6.84 | 6.68 | 6.74 | 6.8 | 6.85 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75.89 | 75.89 | 75.45 | 75.45 | 75.45 | 75.45 | 75.46 | 75.46 | 75.46 | 75.46 |
| FII | 4.92 | 5.06 | 5.76 | 5.62 | 7.57 | 7.58 | 7.36 | 7.18 | 7.39 | 7.11 |
| DII | 13.25 | 13.19 | 12.71 | 12.71 | 10.72 | 10.72 | 11.08 | 11.2 | 10.93 | 11.16 |
| Public | 7.16 | 7.08 | 6.7 | 6.84 | 6.89 | 6.88 | 6.72 | 6.78 | 6.85 | 6.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 101.22 | 101.22 | 100.62 | 100.62 | 100.62 | 100.62 | 100.62 | 100.62 | 100.62 | 100.62 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
